MiTF is Associated with Chemoresistance to Cisplatin in A549 Lung Cancer Cells via Modulating Lysosomal Biogenesis and Autophagy

BACKGROUND: Non-small cell lung carcinoma (NSCLC) is often fatal; advanced NSCLC has a 5-year survival rate less than 20%. Platinum-based chemotherapy, in particular, cis-diamminedichloroplatinum (II) (cisplatin or DDP), is employed for the treatment of NSCLC; however, the drug resistance occurs fre...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Wei, Qin, Xia, Wang, Bin, Xu, Ge, Zhang, Jun, Jiang, Xuejun, Chen, Chengzhi, Qiu, Feng, Zou, Zhen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7398682/
https://www.ncbi.nlm.nih.gov/pubmed/32801894
http://dx.doi.org/10.2147/CMAR.S255939

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7398682/
https://www.ncbi.nlm.nih.gov/pubmed/32801894
http://dx.doi.org/10.2147/CMAR.S255939

Ejemplares similares